Date: August 7th , 2024
Recently, Clinical Service Center completed the acquisition of Jiangsu Pu Er Jing Biopharmaceutical Co., Ltd. (hereinafter referred to as "Pu Er Jing"), after which Pu Er Jing became a wholly-owned subsidiary of Clinical Service Center.
Pu Er Jing is registered in Taicang, Suzhou, with its laboratory located in the Taicang Qi Xi Biological Silicon Valley. It is a professional contract research organization (CRO) that provides innovative mass spectrometry detection analysis and clinical trial management services. Its service areas include multi-omics analysis by mass spectrometry, protein profiling analysis, biological sample detection analysis, molecular interaction analysis, gene and toxic impurity analysis, mass spectrometry training, and clinical trial project management.
The founder, chairman, and chief technology officer of the company is a world-class expert in proteomics, mass spectrometry, and oncology, especially skilled in the discovery and confirmation of complex large molecular biomarkers. He has nearly 30 years of experience in pharmaceutical R&D and management and has served at several well-known MNCs and domestic well-known pharmaceutical companies. The technical director has more than 20 years of experience in the application and research of mass spectrometry.
Clinical Service Center and Pu Er Jing are upstream and downstream in the industry chain. The acquisition will further enhance the company's industrial chain layout and enhance its competitive advantage. After the acquisition, Clinical Service Center will integrate industrial resources and complement mutual strengths in advanced technologies to fully leverage the synergistic effect and provide customers with better one-stop clinical research services.